These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30113151)

  • 1. [The efficacy of intravenous alendronate for osteoporosis in patients with severe motor intellectual disabilities].
    Kaga Y; Ishii S; Kuroda I; Kamiya Y; Nakamura K; Kanemura H; Sugita K; Aihara M
    No To Hattatsu; 2017 Mar; 49(2):113-9. PubMed ID: 30113151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation.
    Imai K
    Clin Interv Aging; 2013; 8():681-8. PubMed ID: 23766643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
    Vis M; Bultink IE; Dijkmans BA; Lems WF
    Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alendronate for the treatment of osteoporosis in men.
    Olszynski WP; Davison KS
    Expert Opin Pharmacother; 2008 Feb; 9(3):491-8. PubMed ID: 18220499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
    Miller PD; McCarthy EF
    Semin Arthritis Rheum; 2015 Apr; 44(5):477-482. PubMed ID: 25312241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
    Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
    N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months.
    Heervä E; Huilaja L; Leinonen P; Peltonen S; Peltonen J
    Calcif Tissue Int; 2014 Jun; 94(6):608-12. PubMed ID: 24390519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.
    Orimo H; Nakamura T; Fukunaga M; Ohta H; Hosoi T; Uemura Y; Kuroda T; Miyakawa N; Ohashi Y; Shiraki M;
    Curr Med Res Opin; 2011 Jun; 27(6):1273-84. PubMed ID: 21554143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate improves screw fixation in osteoporotic bone.
    Moroni A; Faldini C; Hoang-Kim A; Pegreffi F; Giannini S
    J Bone Joint Surg Am; 2007 Jan; 89(1):96-101. PubMed ID: 17200316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.
    Al-Bogami MM; Alkhorayef MA; Bystrom J; Akanle OA; Al-Adhoubi NK; Jawad AS; Mageed RA
    Saudi Med J; 2015 Nov; 36(11):1305-11. PubMed ID: 26593163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of alendronate in the treatment of low bone density in the pediatric and young adult population.
    Dominguez-Bartmess SN; Tandberg D; Cheema AM; Szalay EA
    J Bone Joint Surg Am; 2012 May; 94(10):e62. PubMed ID: 22617928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis.
    Kusamori K; Katsumi H; Abe M; Ueda A; Sakai R; Hayashi R; Hirai Y; Quan YS; Kamiyama F; Sakane T; Yamamoto A
    J Bone Miner Res; 2010 Dec; 25(12):2582-91. PubMed ID: 20533374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.